Goldman Sachs Maintains Buy on Viridian Therapeutics, Lowers Price Target to $36

Benzinga Newsdesk www.benzinga.com Negative 43.3%

Neg 43.3% Neu 0% Pos 0%

Goldman Sachs analyst Richard Law maintains Viridian Therapeutics (NASDAQ:VRDN) with a Buy and lowers the price target from $41 to $36.